CA
NZ
UK
AU
IND
US
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) received FDA approval for Zanvastro to treat Alexander disease in both children and adults.
Aethlon Medical, Inc. (NASDAQ: AEMD) secured a notice of allowance from the USPTO for a patent regarding technology for managing viral infections and their symptoms.
Modular Medical, Inc. (NASDAQ: MODD) secured FDA 510(k) clearance for software updates to its Pivot tubeless insulin pump, a move that enhances user-interface features and bolus delivery options.
Penny stock Hyperfine (NASDAQ:HYPR) is a medical-technology company that has developed a portable, AI-powered magnetic-resonance-imaging system, marketed as the Swoop system, designed to provide brain imaging at the point of care. Shares closed at $0.84 at last closing, up 3.85%.
Becton Dickinson (NYSE:BDX), known as BD, is a leading global medical-technology company that makes and sells medical devices, instrument systems, and reagents, spanning medication delivery and management, diagnostics, and biosciences. Shares closed at $187.62 at last closing, up 0.05%.
Oculis Holding (NASDAQ:OCS) is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic and related diseases, with a pipeline that includes candidates for conditions such as diabetic macular edema, dry-eye disease, and, notably, acute optic neuritis, a neuro-ophthalmic condition. Shares closed at $12.17 …
Penny stock OKYO Pharma (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing therapies for ophthalmic and inflammatory diseases, with its lead candidate, urcosimod, being studied for neuropathic corneal pain, a serious and underserved eye condition, and for dry-eye disease. Shares closed at $1.55 at last …
This clinical-stage oncology penny stock, PMV Pharmaceuticals (NASDAQ:PMVP), is developing cancer therapies that target the p53 tumor-suppressor pathway, one of the most commonly mutated pathways in cancer. Shares closed at $1.24 at last closing, down 1.59%.
Ultragenyx Pharmaceutical (NASDAQ:RARE) shares closed at $14.85 at last closing, down 44.03%, after the company announced that its Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from baseline in Bayley-4 cognitive raw score, nor …
MediWound (NASDAQ:MDWD) is a biopharmaceutical company focused on wound care and tissue repair, with products and candidates that use enzymatic technologies to remove dead or damaged tissue. Shares closed at $13.21 at last closing, up 1.15%.
Please wait processing your request...